Clinical Efficacy and its Quality of Life of Aidi Injection Combined with Taxol and Platinum-based Drug in the Treatment of Elderly Patients with Middle-late Stage Non-small Cell Lung Cancer
LIU Taifeng, CHEN Xiangmei, QIN Xiaobing
The Xuzhou First People's Hospital, Jiangsu Xuzhou 221000, China
Abstract：Objective: To evaluate the clinical effect and its influence on the quality of life of Aidi injection combined with chemotherapy of taxol and Platinum-based drug in the treatment of elderly patients with middle-late stage non-small cell lung cancer. Methods: 60 patients with advanced non-small cell lung cancer patients were randomly divided into observation group and control group, the control group in first, 8 days with paclitaxel, given cis-platinum complexes on the first day, the observation group were given intravenous injection Addie on the basis of the control group. With 1 cycles per 21 d, each patient completed at least 2 cycles of chemotherapy. The clinical efficacy of two groups and their influence on the quality of life of patients were observed and compared. Results: Comparison of the clinical efficacy of the two groups after treatment, the difference was not statistically significant (Z=-1.202, P>0.05), but the effective rate of the observation group was higher than that of the control group. The observation group patients to improve the quality of life was significantly higher than that of control group, the difference was statistically significant (χ2=4.022, P<0.05). There was no significant difference between the observation group and the control group in allergic reaction, alopecia and neurotoxicity (P>0.05), but there was significant difference between the two groups in incidence of adverse reactions of digestive tract (χ2 = 1.663, P <0.05). Conclusion: Aidi injection combined with chemotherapy of taxol and Platinum-based drug in the treatment,it can alleviate the clinical symptoms of elderly patients with advanced non-small cell lung cancer, improve the quality of life, and alleviate the adverse drug reactions caused by chemotherapy.
刘太锋,陈香梅,秦晓冰. 艾迪注射液联合紫杉醇与铂类治疗中老年中晚期非小细胞肺癌的疗效评价[J]. 河北医学, 2017, 23(12): 1981-1983.
LIU Taifeng, CHEN Xiangmei, QIN Xiaobing. Clinical Efficacy and its Quality of Life of Aidi Injection Combined with Taxol and Platinum-based Drug in the Treatment of Elderly Patients with Middle-late Stage Non-small Cell Lung Cancer. HeBei Med, 2017, 23(12): 1981-1983.
[1] 陆守荣,温浩,宋惠珠,等.艾迪注射液联合紫杉醇与奥沙利铂化疗治疗老年中晚期非小细胞肺癌的临床研究[J].中国临床药理学杂志,2016,32(18):1660~1662. [2] Socinski M A, Morris D E, Masters G A, et al. Chemotherapeutic management of stage IV non-small cell lung cancer[J].Chest, 2003, 123(1 Suppl):226S. [3] 周彩存.NCCN2008年非小细胞肺癌临床实践指南更新[J].肿瘤,2008,28(3):183~186. [4] 田杰,贾玫,李潇,等.艾迪注射液改善肿瘤患者生活质量的研究进展[J].中国肿瘤临床与康复,2012,18(2):187~189. [5] 席青,王建清,常小红.艾迪注射液在肺癌治疗中的研究进展[J].中国医药导报,2014,11(4):163~165. [6] 庄岩,魏岩.艾迪注射液联合紫杉醇加顺铂治疗中晚期非小细胞肺癌的临床观察[J].中国临床实用医学,2010,4(7):198. [7] 陆守荣,温浩,宋惠珠,等. 艾迪注射液联合紫杉醇与奥沙利铂化疗治疗老年中晚期非小细胞肺癌的临床研究[J].中国临床药理学杂志,2016,32(18):1660~1662. [8] 赵华叶,李国辉,戚姝娅,等.艾迪注射液联合紫杉醇和顺铂治疗中晚期非小细胞肺癌疗效和安全性的Meta分析[J].中国药房,2016,26(9):1210~1213. [9] 伍家鸣,王菁,林丽珠,等.艾迪注射液联合一线化疗方案治疗非小细胞肺癌临床疗效的Meta分析[J].中成药,2017,39(6):1323~1328. [10] Zhang H, Jiang H, Hu X, et al. Aidi injection combined with radiation in the treatment of non-small cell lung cancer: A meta-analysis evaluation the efficacy and side effects[J].Journal of Cancer Research & Therapeutics, 2015, 11 Suppl(5):c118~21. [11] 苏卫, 王彦,李海婷.艾迪注射液联合紫杉醇加顺铂治疗中晚期非小细胞肺癌的临床观察[J].中国误诊学杂志,2008,8(4):785~786. [12] 刘尚辉,范婷,肖莎,等.草酸铂治疗进展期结直肠癌疗效与ERCC1、ERCC2/XPD基因多态关联的Meta分析[J].中国现代医学杂志,2015,25(3):1~6.
2017, Vol. 23 
冀公网安备13080202000786号